Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112


Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.

Blotner S, Chen LC, Ferlini C, Zhi J.

Cancer Chemother Pharmacol. 2018 Mar;81(3):597-607. doi: 10.1007/s00280-018-3534-7. Epub 2018 Feb 1.


Epstein-Barr Virus MicroRNA Expression Increases Aggressiveness of Solid Malignancies.

Pandya D, Mariani M, He S, Andreoli M, Spennato M, Dowell-Martino C, Fiedler P, Ferlini C.

PLoS One. 2015 Sep 16;10(9):e0136058. doi: 10.1371/journal.pone.0136058. eCollection 2015.


Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer.

Donato MD, Fanelli M, Mariani M, Raspaglio G, Pandya D, He S, Fiedler P, Petrillo M, Scambia G, Ferlini C.

Am J Cancer Res. 2015 May 15;5(6):1862-77. eCollection 2015.


Defining "mutation" and "polymorphism" in the era of personal genomics.

Karki R, Pandya D, Elston RC, Ferlini C.

BMC Med Genomics. 2015 Jul 15;8:37. doi: 10.1186/s12920-015-0115-z.


Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer.

Prislei S, Martinelli E, Zannoni GF, Petrillo M, Filippetti F, Mariani M, Mozzetti S, Raspaglio G, Scambia G, Ferlini C.

Oncotarget. 2015 Aug 7;6(22):18966-79.


Cyparissins A and B, jatrophane diterpenes from Euphorbia cyparissias as Pgp inhibitors and cytotoxic agents against ovarian cancer cell lines.

Lanzotti V, Barile E, Scambia G, Ferlini C.

Fitoterapia. 2015 Jul;104:75-9. doi: 10.1016/j.fitote.2015.05.012. Epub 2015 May 20.


From Protein Communication to Drug Discovery.

Persico M, Di Dato A, Orteca N, Fattorusso C, Novellino E, Andreoli M, Ferlini C.

Curr Top Med Chem. 2015;15(20):2019-31. Review.


Class III β-tubulin in normal and cancer tissues.

Mariani M, Karki R, Spennato M, Pandya D, He S, Andreoli M, Fiedler P, Ferlini C.

Gene. 2015 Jun 1;563(2):109-14. doi: 10.1016/j.gene.2015.03.061. Epub 2015 Apr 1. Review.


Herpes virus microRNA expression and significance in serous ovarian cancer.

Pandya D, Mariani M, McHugh M, Andreoli M, Sieber S, He S, Dowell-Martino C, Fiedler P, Scambia G, Ferlini C.

PLoS One. 2014 Dec 8;9(12):e114750. doi: 10.1371/journal.pone.0114750. eCollection 2014.


Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells.

Andreoli M, Persico M, Kumar A, Orteca N, Kumar V, Pepe A, Mahalingam S, Alegria AE, Petrella L, Sevciunaite L, Camperchioli A, Mariani M, Di Dato A, Novellino E, Scambia G, Malhotra SV, Ferlini C, Fattorusso C.

J Med Chem. 2014 Oct 9;57(19):7916-32. doi: 10.1021/jm5009902. Epub 2014 Sep 26.


GTP is an allosteric modulator of the interaction between the guanylate-binding protein 1 and the prosurvival kinase PIM1.

Persico M, Petrella L, Orteca N, Di Dato A, Mariani M, Andreoli M, De Donato M, Scambia G, Novellino E, Ferlini C, Fattorusso C.

Eur J Med Chem. 2015 Feb 16;91:132-44. doi: 10.1016/j.ejmech.2014.07.093. Epub 2014 Jul 27.


Integrated multidimensional analysis is required for accurate prognostic biomarkers in colorectal cancer.

Mariani M, He S, McHugh M, Andreoli M, Pandya D, Sieber S, Wu Z, Fiedler P, Shahabi S, Ferlini C.

PLoS One. 2014 Jul 2;9(7):e101065. doi: 10.1371/journal.pone.0101065. eCollection 2014.


HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer.

Mariani M, McHugh M, Petrillo M, Sieber S, He S, Andreoli M, Wu Z, Fiedler P, Scambia G, Shahabi S, Ferlini C.

Oncotarget. 2014 Jul 15;5(13):4855-67.


Sox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressiveness.

Raspaglio G, Petrillo M, Martinelli E, Li Puma DD, Mariani M, De Donato M, Filippetti F, Mozzetti S, Prislei S, Zannoni GF, Scambia G, Ferlini C.

Gene. 2014 Jun 1;542(2):173-81. doi: 10.1016/j.gene.2014.03.037. Epub 2014 Mar 21.


Free testosterone drives cancer aggressiveness: evidence from US population studies.

Shahabi S, He S, Kopf M, Mariani M, Petrini J, Scambia G, Ferlini C.

PLoS One. 2013 Apr 24;8(4):e61955. doi: 10.1371/journal.pone.0061955. Print 2013.


MiR-200c and HuR in ovarian cancer.

Prislei S, Martinelli E, Mariani M, Raspaglio G, Sieber S, Ferrandina G, Shahabi S, Scambia G, Ferlini C.

BMC Cancer. 2013 Feb 8;13:72. doi: 10.1186/1471-2407-13-72.


βIII-Tubulin: biomarker of taxane resistance or drug target?

Karki R, Mariani M, Andreoli M, He S, Scambia G, Shahabi S, Ferlini C.

Expert Opin Ther Targets. 2013 Apr;17(4):461-72. doi: 10.1517/14728222.2013.766170. Epub 2013 Feb 2. Review.


Gli family transcription factors are drivers of patupilone resistance in ovarian cancer.

Mozzetti S, Martinelli E, Raspaglio G, Prislei S, De Donato M, Filippetti F, Shahabi S, Scambia G, Ferlini C.

Biochem Pharmacol. 2012 Dec 1;84(11):1409-18. doi: 10.1016/j.bcp.2012.08.019. Epub 2012 Sep 1.


Adrenomedullin in ovarian cancer: foe in vitro and friend in vivo?

Baranello C, Mariani M, Andreoli M, Fanelli M, Martinelli E, Ferrandina G, Scambia G, Shahabi S, Ferlini C.

PLoS One. 2012;7(7):e40678. doi: 10.1371/journal.pone.0040678. Epub 2012 Jul 30.


Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer.

Mariani M, Zannoni GF, Sioletic S, Sieber S, Martino C, Martinelli E, Coco C, Scambia G, Shahabi S, Ferlini C.

Clin Cancer Res. 2012 May 15;18(10):2964-75. doi: 10.1158/1078-0432.CCR-11-2318. Epub 2012 Mar 21.


Novel drugs targeting microtubules: the role of epothilones.

Ferrandina G, Mariani M, Andreoli M, Shahabi S, Scambia G, Ferlini C.

Curr Pharm Des. 2012;18(19):2793-803. Review.


Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability.

La Regina G, Bai R, Rensen W, Coluccia A, Piscitelli F, Gatti V, Bolognesi A, Lavecchia A, Granata I, Porta A, Maresca B, Soriani A, Iannitto ML, Mariani M, Santoni A, Brancale A, Ferlini C, Dondio G, Varasi M, Mercurio C, Hamel E, Lavia P, Novellino E, Silvestri R.

J Med Chem. 2011 Dec 22;54(24):8394-406. doi: 10.1021/jm2012886. Epub 2011 Nov 21.


Class III β-tubulin (TUBB3): more than a biomarker in solid tumors?

Mariani M, Shahabi S, Sieber S, Scambia G, Ferlini C.

Curr Mol Med. 2011 Dec;11(9):726-31. Review.


Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.

De Donato M, Mariani M, Petrella L, Martinelli E, Zannoni GF, Vellone V, Ferrandina G, Shahabi S, Scambia G, Ferlini C.

J Cell Physiol. 2012 Mar;227(3):1034-41. doi: 10.1002/jcp.22813.


Investigation of the Bcl-2 multimerisation process: structural and functional implications.

Camperchioli A, Mariani M, Bartollino S, Petrella L, Persico M, Orteca N, Scambia G, Shahabi S, Ferlini C, Fattorusso C.

Biochim Biophys Acta. 2011 May;1813(5):850-7. doi: 10.1016/j.bbamcr.2011.02.006. Epub 2011 Feb 12.


RON and cisplatin resistance in ovarian cancer cell lines.

Prislei S, Mariani M, Raspaglio G, Mozzetti S, Filippetti F, Ferrandina G, Scambia G, Ferlini C.

Oncol Res. 2010;19(1):13-22.


Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts.

De Stefano I, Battaglia A, Zannoni GF, Prisco MG, Fattorossi A, Travaglia D, Baroni S, Renier D, Scambia G, Ferlini C, Gallo D.

Cancer Chemother Pharmacol. 2011 Jul;68(1):107-16. doi: 10.1007/s00280-010-1462-2. Epub 2010 Sep 17.


HuR regulates beta-tubulin isotype expression in ovarian cancer.

Raspaglio G, De Maria I, Filippetti F, Martinelli E, Zannoni GF, Prislei S, Ferrandina G, Shahabi S, Scambia G, Ferlini C.

Cancer Res. 2010 Jul 15;70(14):5891-900. doi: 10.1158/0008-5472.CAN-09-4656. Epub 2010 Jun 29.


The epithelial-mesenchymal transition and the estrogen-signaling in ovarian cancer.

Gallo D, Ferlini C, Scambia G.

Curr Drug Targets. 2010 Apr;11(4):474-81. Review.


IgG autoantibody to brain beta tubulin III associated with cytokine cluster-II discriminate cerebral malaria in central India.

Bansal D, Herbert F, Lim P, Deshpande P, Bécavin C, Guiyedi V, de Maria I, Rousselle JC, Namane A, Jain R, Cazenave PA, Mishra GC, Ferlini C, Fesel C, Benecke A, Pied S.

PLoS One. 2009 Dec 14;4(12):e8245. doi: 10.1371/journal.pone.0008245.


Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers.

Di Michele M, Marcone S, Cicchillitti L, Della Corte A, Ferlini C, Scambia G, Donati MB, Rotilio D.

J Proteomics. 2010 Mar 10;73(5):879-98. doi: 10.1016/j.jprot.2009.11.012. Epub 2009 Dec 3.


Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57.

Cicchillitti L, Di Michele M, Urbani A, Ferlini C, Donat MB, Scambia G, Rotilio D.

J Proteome Res. 2009 Apr;8(4):1902-12.


Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77.

Ferlini C, Cicchillitti L, Raspaglio G, Bartollino S, Cimitan S, Bertucci C, Mozzetti S, Gallo D, Persico M, Fattorusso C, Campiani G, Scambia G.

Cancer Res. 2009 Sep 1;69(17):6906-14. doi: 10.1158/0008-5472.CAN-09-0540. Epub 2009 Aug 11.


Vinorelbine induces beta3-tubulin gene expression through an AP-1 Site.

Saussede-Aim J, Matera EL, Herveau S, Rouault JP, Ferlini C, Dumontet C.

Anticancer Res. 2009 Aug;29(8):3003-9.


Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma.

De Stefano I, Raspaglio G, Zannoni GF, Travaglia D, Prisco MG, Mosca M, Ferlini C, Scambia G, Gallo D.

Biochem Pharmacol. 2009 Dec 1;78(11):1374-81. doi: 10.1016/j.bcp.2009.07.011. Epub 2009 Jul 28.


Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.

Ferrandina G, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Ferlini C, Danesi R, Scambia G, Del Tacca M.

Cancer Chemother Pharmacol. 2010 Mar;65(4):679-86. doi: 10.1007/s00280-009-1073-y. Epub 2009 Jul 29.


Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway.

Saussede-Aim J, Matera EL, Ferlini C, Dumontet C.

Cell Motil Cytoskeleton. 2009 Jul;66(7):378-88. doi: 10.1002/cm.20377.


Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin.

Pepe A, Sun L, Zanardi I, Wu X, Ferlini C, Fontana G, Bombardelli E, Ojima I.

Bioorg Med Chem Lett. 2009 Jun 15;19(12):3300-4. doi: 10.1016/j.bmcl.2009.04.070. Epub 2009 Apr 22.


Molecular mechanisms of patupilone resistance.

Mozzetti S, Iantomasi R, De Maria I, Prislei S, Mariani M, Camperchioli A, Bartollino S, Gallo D, Scambia G, Ferlini C.

Cancer Res. 2008 Dec 15;68(24):10197-204. doi: 10.1158/0008-5472.CAN-08-2091.


Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.

Meco D, Servidei T, Riccardi A, Ferlini C, Cusano G, Zannoni GF, Giangaspero F, Riccardi R.

Neuro Oncol. 2009 Jun;11(3):250-9. doi: 10.1215/15228517-2008-095. Epub 2008 Nov 25.


A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines.

Di Michele M, Della Corte A, Cicchillitti L, Del Boccio P, Urbani A, Ferlini C, Scambia G, Donati MB, Rotilio D.

Biochim Biophys Acta. 2009 Feb;1794(2):225-36. doi: 10.1016/j.bbapap.2008.09.017. Epub 2008 Oct 10.


Role of microRNAs in drug-resistant ovarian cancer cells.

Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C.

Gynecol Oncol. 2008 Dec;111(3):478-86. doi: 10.1016/j.ygyno.2008.08.017. Epub 2008 Sep 26.


Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.

Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R.

Int J Cancer. 2008 Dec 15;123(12):2939-49. doi: 10.1002/ijc.23902.


Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients.

Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zucconi A, Santaguida S, Zannoni G, Scambia G, Ferlini C.

Gynecol Oncol. 2008 Nov;111(2):237-43. doi: 10.1016/j.ygyno.2008.07.013. Epub 2008 Aug 20.


Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin.

Cicchillitti L, Penci R, Di Michele M, Filippetti F, Rotilio D, Donati MB, Scambia G, Ferlini C.

Mol Cancer Ther. 2008 Jul;7(7):2070-9. doi: 10.1158/1535-7163.MCT-07-2370.


Soy phytochemicals decrease nonsmall cell lung cancer growth in female athymic mice.

Gallo D, Zannoni GF, De Stefano I, Mosca M, Ferlini C, Mantuano E, Scambia G.

J Nutr. 2008 Jul;138(7):1360-4.


New taxanes in development.

Ferlini C, Gallo D, Scambia G.

Expert Opin Investig Drugs. 2008 Mar;17(3):335-47. doi: 10.1517/13543784.17.3.335 . Review.


Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work?

Ferlini C, Raspaglio G, Cicchillitti L, Mozzetti S, Prislei S, Bartollino S, Scambia G.

Curr Cancer Drug Targets. 2007 Dec;7(8):704-12. Review.


From plasma membrane to cytoskeleton: a novel function for semaphorin 6A.

Prislei S, Mozzetti S, Filippetti F, De Donato M, Raspaglio G, Cicchillitti L, Scambia G, Ferlini C.

Mol Cancer Ther. 2008 Jan;7(1):233-41. doi: 10.1158/1535-7163.MCT-07-0390. Epub 2008 Jan 9.


Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region.

Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, Cicchillitti L, Mozzetti S, Scambia G, Ferlini C.

Gene. 2008 Feb 15;409(1-2):100-8. doi: 10.1016/j.gene.2007.11.015. Epub 2007 Dec 3.


Supplemental Content

Loading ...
Support Center